You are here

FDA Approves Isentress (Raltegravir) for Oral Suspension in Pediatric HIV Patients

Product also available in tablet form (January 8)

The FDA has approved Isentress (Merck) for oral suspension, a new pediatric formulation of the integrase inhibitor raltegravir. With this approval, Isentress is now indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency-1 (HIV-1) infection in patients 4 weeks of age and older.

The use of other active agents with Isentress is associated with a greater likelihood of a treatment response. The oral suspension may be used in patients as young as 4 weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of Isentress have not been established in infants younger than 4 weeks of age.

Formulations of Isentress for specific populations now include oral suspension, chewable tablets, and film-coated tablets.

Isentress (raltegravir) works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells.

Source: Merck; January 8, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress